

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 55 years Female

Specimen Collected: 7/18/2025 11:00 MDT

Haloperidol Level	 Received: 7/18/2025 11:00 MDT	Report/Verified: 7/18/2025 11:24 MDT	
Procedure	Result	Units	Reference Interval
Haloperidol	10.1 # i1	ng/mL	[1.0-10.0]

Test Information

i1: Haloperidol
INTERPRETIVE INFORMATION: Haloperidol Level

Therapeutic Range: 1.0-10.0 ng/mL

Toxic: Greater than or equal to 15.0 ng/mL

The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to haloperidol therapy may include drowsiness, blurred vision, tardive dyskinesia, tachycardia, hypotension, and muscular rigidity.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H=High, i=Test Information, L=Low, t=Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 25-199-900007**Report Request ID:** 20596137**Printed:** 7/18/2025 11:24 MDT

Page 1 of 1